Vaxcyte, Inc. (PCVX)
| Previous Close | 60.88 |
| Open | 61.05 |
| Bid | 60.34 x 100 |
| Ask | 60.55 x 100 |
| Day's Range | 59.98 - 61.98 |
| 52 Week Range | 41.57 - 82.04 |
| Volume | |
| Avg. Volume | 858,111 |
| Market Cap | 6.574B |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.14 |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 103.29 |
GlobeNewswireVaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media se
GuruFocus.comSutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances
Full Year Earnings Reveal Strong Revenue Growth but Operational Challenges Persist
GuruFocus.comInsider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 Shares
Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte Inc (NASDAQ:PCVX), has sold 8,000 shares of the company on March 18, 2024, according to a recent SEC filing.
